Relationship between enkephalinase inhibition of thiorphan in vivo and its analgesic activity. 1985

M Hachisu, and H Takahashi, and T Hiranuma, and Y Shibazaki, and S Murata

The relationship between enkephalinase inhibition by thiorphan in vivo and analgesic activity in nociceptive tests was studied. The analgesic activity of thiorphan in various nociceptive tests was compared with that of a narcotic analgesic, morphine and antipyretic analgesic, antipyrine. Tail-flick test revealed that thiorphan applied intracerebroventricularly (i.c.v.) or intraperitoneally (i.p.) in rats markedly potentiated the analgesic activity of [D-Ala2, Met5]-enkephalin administered i.c.v. The amount of thiorphan in the mouse brain and the fragments of Met-enkephalin degraded by brain homogenate were assayed after intraperitoneal administration of 300 mg/kg thiorphan. The concentration of thiorphan in the brain arised to 18.2 +/- 2.4 nmol/g brain 30 min after intraperitoneal administration of thiorphan and then it quickly disappeared from the brain. As to the fragments of Met-enkephalin degraded by brain homogenate after i.p. administration of thiorphan, the concentration of tyrosine and tyrosyl-glycine (Tyr-Gly) was the same as that of the vehicle control, whereas only the amount of tyrosyl-glycyl-glycine (Tyr-Gly-Gly) decreased to 21.5% of the control value after 30 min, and then it recovered to 75% after 180 min. Thus, thiorphan inhibited enkephalinase activity alone demonstrating selective activity. Thiorphan at doses of 30-300 mg/kg demonstrated analgesic activity in the nociceptive tests of acetic acid writhing, hot-plate and tail-flick, whereas it did not have any activity in the tail-pinch test. Morphine showed analgesic activity in the four nociceptive tests employed. Antipyrine showed analgesic activity in three nociceptive tests but not in the tail-flick test. The dose response curves for morphine and antipyrine were parallel. The slope of the dose response curve for thiorphan, however, was shallower than those for two reference analgesics used. The role of main enkephalin degrading enzymes in the brain was discussed with respect to the analgesic action of thiorphan and its concentration in the brain.

UI MeSH Term Description Entries
D007276 Injections, Intraventricular Injections into the cerebral ventricles. Intraventricular Injections,Injection, Intraventricular,Intraventricular Injection
D008297 Male Males
D008625 Tiopronin Sulfhydryl acylated derivative of GLYCINE. Mercaptopropionylglycine,Thiopronine,2-Mercaptopropionylglycine,2-Thiol-propionamido-acetic Acid,2-Thiolpropionamidoacetic Acid,Acadione,Captimer,Meprin,Thiola,Tiopronine,alpha-Mercaptopropionylglycine,2 Mercaptopropionylglycine,2 Thiol propionamido acetic Acid,2 Thiolpropionamidoacetic Acid,Acid, 2-Thiol-propionamido-acetic,Acid, 2-Thiolpropionamidoacetic,alpha Mercaptopropionylglycine
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D009419 Nerve Tissue Proteins Proteins, Nerve Tissue,Tissue Proteins, Nerve
D009619 Nociceptors Peripheral AFFERENT NEURONS which are sensitive to injuries or pain, usually caused by extreme thermal exposures, mechanical forces, or other noxious stimuli. Their cell bodies reside in the DORSAL ROOT GANGLIA. Their peripheral terminals (NERVE ENDINGS) innervate target tissues and transduce noxious stimuli via axons to the CENTRAL NERVOUS SYSTEM. Pain Receptors,Receptors, Pain,Nociceptive Neurons,Neuron, Nociceptive,Neurons, Nociceptive,Nociceptive Neuron,Nociceptor,Pain Receptor
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D011930 Reaction Time The time from the onset of a stimulus until a response is observed. Response Latency,Response Speed,Response Time,Latency, Response,Reaction Times,Response Latencies,Response Times,Speed, Response,Speeds, Response
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon

Related Publications

M Hachisu, and H Takahashi, and T Hiranuma, and Y Shibazaki, and S Murata
August 1985, The Journal of pharmacology and experimental therapeutics,
M Hachisu, and H Takahashi, and T Hiranuma, and Y Shibazaki, and S Murata
June 1983, Proceedings of the National Academy of Sciences of the United States of America,
M Hachisu, and H Takahashi, and T Hiranuma, and Y Shibazaki, and S Murata
October 1983, European journal of pharmacology,
M Hachisu, and H Takahashi, and T Hiranuma, and Y Shibazaki, and S Murata
November 1980, Nature,
M Hachisu, and H Takahashi, and T Hiranuma, and Y Shibazaki, and S Murata
November 1987, The Journal of pharmacology and experimental therapeutics,
M Hachisu, and H Takahashi, and T Hiranuma, and Y Shibazaki, and S Murata
January 1982, Advances in biochemical psychopharmacology,
M Hachisu, and H Takahashi, and T Hiranuma, and Y Shibazaki, and S Murata
April 1985, Life sciences,
M Hachisu, and H Takahashi, and T Hiranuma, and Y Shibazaki, and S Murata
May 1983, Brain research,
M Hachisu, and H Takahashi, and T Hiranuma, and Y Shibazaki, and S Murata
January 1986, Functional neurology,
M Hachisu, and H Takahashi, and T Hiranuma, and Y Shibazaki, and S Murata
June 1984, European journal of pharmacology,
Copied contents to your clipboard!